Last reviewed · How we verify
Salmeterol(SN408D)
Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Asthma maintenance therapy (in combination with inhaled corticosteroid), Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Salmeterol(SN408D) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Salmeterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation and airway dilation. Its long duration of action (12 hours) is due to its lipophilic properties, which allow it to partition into airway tissue and provide sustained receptor activation. It is typically used in combination with inhaled corticosteroids for maintenance therapy in asthma and COPD.
Approved indications
- Asthma maintenance therapy (in combination with inhaled corticosteroid)
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salmeterol(SN408D) CI brief — competitive landscape report
- Salmeterol(SN408D) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI